107 related articles for article (PubMed ID: 31197519)
1. ASO Author Reflections: ASCL2, a Marker of Dynamic Colon Stem Cell, Involved in Wnt Pathway Activation Reflects Anti-cancer Drug Resistance in Primary Colorectal Cancer.
Tanaka T; Yamashita K
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):634. PubMed ID: 31197519
[No Abstract] [Full Text] [Related]
2. Comprehensive Genetic Search to Clarify the Molecular Mechanism of Drug Resistance Identifies ASCL2-LEF1/TSPAN8 Axis in Colorectal Cancer.
Tanaka T; Kojima K; Yokota K; Tanaka Y; Ooizumi Y; Ishii S; Nishizawa N; Yokoi K; Ushiku H; Kikuchi M; Kojo K; Minatani N; Katoh H; Sato T; Nakamura T; Sawanobori M; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 May; 26(5):1401-1411. PubMed ID: 30706227
[TBL] [Abstract][Full Text] [Related]
3. A Positive Regulatory Loop between a Wnt-Regulated Non-coding RNA and ASCL2 Controls Intestinal Stem Cell Fate.
Giakountis A; Moulos P; Zarkou V; Oikonomou C; Harokopos V; Hatzigeorgiou AG; Reczko M; Hatzis P
Cell Rep; 2016 Jun; 15(12):2588-96. PubMed ID: 27292638
[TBL] [Abstract][Full Text] [Related]
4. Ascl2 acts as an R-spondin/Wnt-responsive switch to control stemness in intestinal crypts.
Schuijers J; Junker JP; Mokry M; Hatzis P; Koo BK; Sasselli V; van der Flier LG; Cuppen E; van Oudenaarden A; Clevers H
Cell Stem Cell; 2015 Feb; 16(2):158-70. PubMed ID: 25620640
[TBL] [Abstract][Full Text] [Related]
5. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
6. In situ validation of an intestinal stem cell signature in colorectal cancer.
Ziskin JL; Dunlap D; Yaylaoglu M; Fodor IK; Forrest WF; Patel R; Ge N; Hutchins GG; Pine JK; Quirke P; Koeppen H; Jubb AM
Gut; 2013 Jul; 62(7):1012-23. PubMed ID: 22637696
[TBL] [Abstract][Full Text] [Related]
7. Entopic overexpression of Ascl2 does not accelerate tumourigenesis in ApcMin mice.
Reed KR; Tunster SJ; Young M; Carrico A; John RM; Clarke AR
Gut; 2012 Oct; 61(10):1435-8. PubMed ID: 22138533
[TBL] [Abstract][Full Text] [Related]
8. Ascl2 reinforces intestinal stem cell identity.
Yan KS; Kuo CJ
Cell Stem Cell; 2015 Feb; 16(2):105-6. PubMed ID: 25658363
[TBL] [Abstract][Full Text] [Related]
9. WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability.
Yokota K; Tanaka Y; Harada H; Kaida T; Nakamoto S; Soeno T; Fujiyama Y; Yokota M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Dec; 26(13):4826-4834. PubMed ID: 31549316
[TBL] [Abstract][Full Text] [Related]
10. The intestinal stem cell regulating gene ASCL2 is required for L1-mediated colon cancer progression.
Basu S; Gavert N; Brabletz T; Ben-Ze'ev A
Cancer Lett; 2018 Jun; 424():9-18. PubMed ID: 29551399
[TBL] [Abstract][Full Text] [Related]
11. E2A attenuates tumor-initiating capacity of colorectal cancer cells via the Wnt/beta-catenin pathway.
Zhao H; Zhao C; Li H; Zhang D; Liu G
J Exp Clin Cancer Res; 2019 Jun; 38(1):276. PubMed ID: 31234887
[TBL] [Abstract][Full Text] [Related]
12. DPEP1 promotes drug resistance in colon cancer cells by forming a positive feedback loop with ASCL2.
Zeng C; Qi G; Shen Y; Li W; Zhu Q; Yang C; Deng J; Lu W; Liu Q; Jin J
Cancer Med; 2023 Jan; 12(1):412-424. PubMed ID: 35670012
[TBL] [Abstract][Full Text] [Related]
13. ASO Author Reflections: ATMIN Altering the WNT Signaling Pathway via PARP1 in MSI-High Colorectal Cancer.
Li YJ; Yang CN; Kuo YP; Lai WT; Wu TS; Lin BR
Ann Surg Oncol; 2021 Dec; 28(13):8555. PubMed ID: 34196862
[No Abstract] [Full Text] [Related]
14. MiR-452 promotes an aggressive colorectal cancer phenotype by regulating a Wnt/β-catenin positive feedback loop.
Li T; Jian X; He H; Lai Q; Li X; Deng D; Liu T; Zhu J; Jiao H; Ye Y; Wang S; Yang M; Zheng L; Zhou W; Ding Y
J Exp Clin Cancer Res; 2018 Sep; 37(1):238. PubMed ID: 30253791
[TBL] [Abstract][Full Text] [Related]
15. CREB-binding protein, p300, butyrate, and Wnt signaling in colorectal cancer.
Bordonaro M; Lazarova DL
World J Gastroenterol; 2015 Jul; 21(27):8238-48. PubMed ID: 26217075
[TBL] [Abstract][Full Text] [Related]
16. Protective C allele of the single-nucleotide polymorphism rs1335532 is associated with strong binding of Ascl2 transcription factor and elevated CD58 expression in B-cells.
Mitkin NA; Muratova AM; Korneev KV; Pavshintsev VV; Rumyantsev KA; Vagida MS; Uvarova AN; Afanasyeva MA; Schwartz AM; Kuprash DV
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3211-3220. PubMed ID: 30006149
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.
Park SY; Kim JY; Choi JH; Kim JH; Lee CJ; Singh P; Sarkar S; Baek JH; Nam JS
Clin Cancer Res; 2019 Feb; 25(4):1415-1429. PubMed ID: 30446587
[TBL] [Abstract][Full Text] [Related]
18. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia.
Jubb AM; Chalasani S; Frantz GD; Smits R; Grabsch HI; Kavi V; Maughan NJ; Hillan KJ; Quirke P; Koeppen H
Oncogene; 2006 Jun; 25(24):3445-57. PubMed ID: 16568095
[TBL] [Abstract][Full Text] [Related]
19. Expression of an ASCL2 related stem cell signature and IGF2 in colorectal cancer liver metastases with 11p15.5 gain.
Stange DE; Engel F; Longerich T; Koo BK; Koch M; Delhomme N; Aigner M; Toedt G; Schirmacher P; Lichter P; Weitz J; Radlwimmer B
Gut; 2010 Sep; 59(9):1236-44. PubMed ID: 20479215
[TBL] [Abstract][Full Text] [Related]
20. Development of Small Molecules Targeting the Wnt Signaling Pathway in Cancer Stem Cells for the Treatment of Colorectal Cancer.
Song L; Li Y; He B; Gong Y
Clin Colorectal Cancer; 2015 Sep; 14(3):133-45. PubMed ID: 25799881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
